Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | AR | P10275 | 3/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948524 | 0.95 | RAB9A (0.91) | RAB9ANPC1BCHEALDH1A1AR | |
| SCHEMBL21639229 | 0.94 | NPC1 (0.88) | RAB9ANPC1BCHEALDH1A1AR | |
| SCHEMBL9729274 | 0.94 | NPC1 (0.88) | RAB9ANPC1BCHEALDH1A1AR | |
| SCHEMBL11535096 | 0.94 | NPC1 (0.88) | RAB9ANPC1BCHEALDH1A1AR | |
| SCHEMBL8098342 | 0.90 | RAB9A (0.82) | RAB9ANPC1BCHEALDH1A1AR | |
| SCHEMBL14304932 | 0.90 | BCHE (0.86) | RAB9ANPC1BCHEALDH1A1AR | |
| SCHEMBL14303261 | 0.88 | BCHE (0.83) | RAB9ANPC1BCHEALDH1A1AR | |
| SCHEMBL6141660 | 0.88 | BCHE (0.83) | RAB9ANPC1BCHEALDH1A1AR | |
| SCHEMBL14303260 | 0.88 | BCHE (0.83) | RAB9ANPC1BCHEALDH1A1AR | |
| SCHEMBL14304381 | 0.88 | BCHE (0.83) | RAB9ANPC1BCHEALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2019-07-11 | — | — | US | disclosed |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20180000793-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | ABEL-SANTOS ERNESTO (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170166524-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166524-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-9611214-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-04 | — | — | US | disclosed |
| US-9611214-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-04 | — | — | US | disclosed |
| WO-2016127102-A2 | INHIBITING GERMINATION OF CLOSTRIDIUM PERFRINGENS SPORES TO REDUCE NECROTIC ENTERITIS | ABEL-SANTOS ERNESTO (US) | 2016-08-11 | — | — | WO | disclosed |
| US-5874501-A | POLY(P-HYDROXYSTYRENE) WITH AROMATIC MOIETY AND ALIPHATIC MOIETY WITH INORGANIC OXIDE | KEEHAN DONALD J (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0407554-B1 | METALLIC OXIDE-OXIRANE POLYMERS AND PREPOLYMERS | KEEHAN DONALD J (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1997031047-A1 | MULTI-FUNCTIONAL OXIRANE POLYMERS | KEEHAN DONALD J (US) | 1997-08-28 | — | — | WO | disclosed |
| US-5658996-A | A LIQUID POLYEPOXIDE PREPOLYMER THE REACTION PRODUCT OF A TRISHYDROXYPHENYL, AN AROMATIC DIGLYCIDYL ETHER AND METAL OXIDE; CURABLE, LOW VISCOSITY; FORMED POLYEPOXIDE IS HEAT AND CHEMICAL RESISTANCE, ELONGATION, TOUGHNESS | KEEHAN DONALD J (US) | 1997-08-19 | — | — | US | disclosed |
| US-5169912-A | Hydrolyzable oxygen bonding with epoxide; silica, titania; high performance coatings, adhesives | KEEHAN DONALD J (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0407554-A4 | METALLIC OXIDE-OXIRANE POLYMERS AND PREPOLYMERS | — | 1992-10-21 | — | — | EP | disclosed |
| US-5026816-A | Reaction product of diglycidyl ether of (bisphenol a or resorcinol) with metallic oxide in presence of imidazole catalyst | KEEHAN DONALD J (US) | 1991-06-25 | — | — | US | disclosed |
| EP-0407554-A1 | METALLIC OXIDE-OXIRANE POLYMERS AND PREPOLYMERS. | KEEHAN DONALD J (US) | 1991-01-16 | — | — | EP | disclosed |
| WO-1990008168-A1 | METALLIC OXIDE-OXIRANE POLYMERS AND PREPOLYMERS | KEEHAN DONALD J (US) | 1990-07-26 | — | — | WO | disclosed |
| US-4880892-A | PHOSPHONIUM OR PHOSPHORANE CATALYST, PROTECTIVE COATINGS | CIBA-GEIGY CORPORATION (US) | 1989-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | CASP3, SI, PYCARD | RAB9A 4497/4885NPC1 1750/4885BCHE 2871/4885 |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | SLC6A2, TPH1, SLC6A3 | RAB9A 503/4885NPC1 701/4885BCHE 1380/4885 |
| US-20170166524-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | RAB9A 503/4885NPC1 701/4885BCHE 1380/4885 |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | RAB9A 4497/4885NPC1 1750/4885BCHE 2871/4885 |
| US-20180000793-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | RAB9A 4497/4885NPC1 1750/4885BCHE 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.